Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectivenessnews2026-04-16T00:05:36+00:00April 16th, 2026|The New York Times|
GLP-1 Experimentation Is Everywhere, and Science Can’t Keep Upnews2026-04-15T21:43:41+00:00April 15th, 2026|The New York Times|
Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billionnews2026-03-31T19:18:06+00:00March 31st, 2026|The New York Times|
How TrumpRx Drug Prices Compare With Those in Other Countriesnews2026-03-18T04:01:07+00:00March 18th, 2026|The New York Times|
TrumpRx Is Set to Go Live on Thursdaynews2026-02-05T17:33:59+00:00February 5th, 2026|The New York Times|
The Key to Managing Tariffs: Be Big and Have the President’s Earnews2026-02-02T20:59:44+00:00February 2nd, 2026|The New York Times|
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Valuenews2025-11-21T21:25:40+00:00November 21st, 2025|The New York Times|
RFK Jr. Walks a Tightrope on Trump Deal for Obesity Drugsnews2025-11-14T10:02:07+00:00November 14th, 2025|The New York Times|
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Dealnews2025-11-08T12:38:25+00:00November 8th, 2025|The New York Times|
What Trump’s New Drug Pricing Deal Means for People With Obesitynews2025-11-06T21:53:59+00:00November 6th, 2025|The New York Times|
